|
APIP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.92300003593249E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.79830000007964E-07 |
| Normal-vs-Stage2 |
1.201090E-04 |
| Normal-vs-Stage3 |
3.37129999472552E-08 |
| Normal-vs-Stage4 |
6.78379999952128E-08 |
| Stage1-vs-Stage2 |
9.447800E-01 |
| Stage1-vs-Stage3 |
1.890400E-01 |
| Stage1-vs-Stage4 |
2.443200E-01 |
| Stage2-vs-Stage3 |
4.464000E-01 |
| Stage2-vs-Stage4 |
3.950000E-01 |
| Stage3-vs-Stage4 |
9.215600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.41319994490163E-09 |
| Normal-vs-AfricanAmerican |
1.055340E-03 |
| Normal-vs-Asian |
7.79830000000592E-05 |
| Caucasian-vs-AfricanAmerican |
8.170600E-01 |
| Caucasian-vs-Asian |
4.812400E-01 |
| AfricanAmerican-vs-Asian |
5.426200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.96310000477595E-08 |
| Normal-vs-Female |
2.43250000142581E-08 |
| Male-vs-Female |
1.870430E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.41240000051913E-07 |
| Normal-vs-Age(41-60Yrs) |
6.90560000293772E-08 |
| Normal-vs-Age(61-80Yrs) |
4.82799999979022E-08 |
| Normal-vs-Age(81-100Yrs) |
2.774100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.626600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.027400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.272000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.031400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.750600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.431400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.955800E-02 |
| Classical-VS-Follicular |
1.140430E-01 |
| Classical-VS-Other |
8.085200E-01 |
| Classical-VS-Normal |
2.20150000451724E-08 |
| Tall-VS-Follicular |
3.335700E-03 |
| Tall-VS-Other |
3.922200E-01 |
| Tall-VS-Normal |
1.44330000173554E-08 |
| Follicular-VS-Other |
5.013800E-01 |
| Follicular-VS-Normal |
2.362800E-03 |
| Other-VS-Normal |
1.047560E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.39120000466997E-08 |
| Normal-vs-N1 |
3.23810001034985E-09 |
| N0-vs-N1 |
9.092000E-02 |
|
|
